National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 5 of 5 Research Studies DisplayedAdamson BJS, Carlson JJ, Kublin JG
The potential cost-effectiveness of pre-exposure prophylaxis combined with HIV vaccines in the United States.
This economic evaluation found that at current prices, pre-exposure prophylaxis (PrEP) was not cost-effective alone or in combination. A combination strategy had the greatest health benefit but was not cost-effective as compared to vaccination alone. Vaccine durability and PrEP drug prices were key drivers of cost-effectiveness.
AHRQ-funded; HS013853.
Citation: Adamson BJS, Carlson JJ, Kublin JG .
The potential cost-effectiveness of pre-exposure prophylaxis combined with HIV vaccines in the United States.
Vaccines 2017 May 24;5(2). doi: 10.3390/vaccines5020013.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Vaccination, Healthcare Costs, Prevention
Adamson B, Dimitrov D, Devine B
The potential cost-effectiveness of HIV vaccines: a systematic review.
The aim of this paper was to review and compare HIV vaccine uncertainty in model, methodology, and parameterization. Model assumptions about vaccine price, HIV treatment costs, epidemic context, and willingness to pay influenced results more consistently than assumptions on HIV transmission dynamics.
AHRQ-funded; HS013853.
Citation: Adamson B, Dimitrov D, Devine B .
The potential cost-effectiveness of HIV vaccines: a systematic review.
Pharmacoeconom Open 2017 Mar;1(1):1-12. doi: 10.1007/s41669-016-0009-9.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Healthcare Costs, Vaccination
Eaton EF, Tamhane A, Saag M
Cost considerations in the current antiretroviral era.
The authors analyzed the relative cost-effectiveness of contemporary antiretroviral therapy in real-world clinical settings. They found that, among the participants studied, raltegravir and efavirenz-based regimens were the most cost-effective options for treatment-naive patients. They suggested that these findings are relevant given changes in recommended regimens for treatment-naive persons. The authors recommended that further data on the comparative effectiveness of efavirenz and rilpivirine are needed.
AHRQ-funded; HS013852.
Citation: Eaton EF, Tamhane A, Saag M .
Cost considerations in the current antiretroviral era.
AIDS 2016 Sep 10;30(14):2115-9. doi: 10.1097/qad.0000000000001120.
.
.
Keywords: Healthcare Costs, Human Immunodeficiency Virus (HIV), Medication
Fleishman JA, Monroe AK, Voss CC
AHRQ Author: Fleishman JA
Expenditures for persons living with HIV enrolled in Medicaid, 2006-2010.
The researchers used Medicaid claims data to comprehensively assess payments for care for persons living with HIV between 2006 and 2010. They found that estimated Medicaid payment amounts are higher than some prior estimates. More complete capture of expensive inpatient hospitalizations in Medicaid data may partially explain this finding.
AHRQ-authored.
Citation: Fleishman JA, Monroe AK, Voss CC .
Expenditures for persons living with HIV enrolled in Medicaid, 2006-2010.
J Acquir Immune Defic Syndr 2016 Aug 1;72(4):408-15. doi: 10.1097/qai.0000000000000985.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Medicaid, Healthcare Costs
Hellinger FJ
AHRQ Author: Hellinger FJ
Hospital use by persons with HIV in the 21st century: a 5-state study.
The purpose of this study was to determine whether reductions in hospital utilization observed immediately after the availability of highly active antiretroviral therapy (between 1995 and 2000) have persisted into the 21st century. It found that the total number of hospitalizations by persons with HIV in the 5 study states fell by one third between 2000 and 2013 even though the number of persons living with HIV increased by >50%.
AHRQ-authored.
Citation: Hellinger FJ .
Hospital use by persons with HIV in the 21st century: a 5-state study.
Med Care 2016 Jun;54(6):639-44. doi: 10.1097/mlr.0000000000000526.
.
.
Keywords: Healthcare Cost and Utilization Project (HCUP), Human Immunodeficiency Virus (HIV), Hospitalization, Healthcare Costs